<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475214</url>
  </required_header>
  <id_info>
    <org_study_id>2705</org_study_id>
    <secondary_id>R01AR060261</secondary_id>
    <nct_id>NCT01475214</nct_id>
  </id_info>
  <brief_title>Musculoskeletal Effects of Bicarbonate</brief_title>
  <official_title>Musculoskeletal Benefits of Bicarbonate in Older Adults - A Dose-Finding Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With aging, men and women develop a mild and progressive metabolic acidosis. This occurs as a&#xD;
      result of declining renal function and ingestion of acid-producing diets. There is extensive&#xD;
      evidence that severe metabolic acidosis causes bone and muscle loss, but the impact of the&#xD;
      chronic, mild acidosis on bone and muscle in older individuals has not been established. In a&#xD;
      recent study, administration of a single dose of bicarbonate daily for 3 months significantly&#xD;
      reduced urinary excretion of N-telopeptide (NTX), a marker of bone resorption and urinary&#xD;
      nitrogen, a marker of muscle wasting and improved muscle performance in the women but not the&#xD;
      men. These and other data support a potential role for bicarbonate as a means of reducing the&#xD;
      musculoskeletal declines that lead to extensive morbidity and mortality in the elderly.&#xD;
      Before proceeding to a long-term bicarbonate intervention study, however, it is important to&#xD;
      identify the dose of bicarbonate most likely to be optimal and to characterize the subjects&#xD;
      who benefit most from it. This double blind, placebo controlled, dose-finding study will&#xD;
      evaluate the effects of placebo and two doses of bicarbonate on urinary NTX and nitrogen&#xD;
      excretion and on lower extremity performance over a 3 month period in 138 men and 138 women,&#xD;
      age 60 and older. Changes in urinary excretion of NTX and nitrogen and in selected measures&#xD;
      of lower extremity performance will be compared across the three groups. The safety and&#xD;
      tolerability of the interventions will also be evaluated. This investigation should provide&#xD;
      needed information on the appropriate dosing regimen for men and women and on the study&#xD;
      population that should be enrolled in a future bicarbonate intervention trial to assess the&#xD;
      long-term effects of this simple, low cost intervention on important clinical outcomes&#xD;
      including rates of loss in bone and muscle mass, falls, and fractures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This dose-finding study will evaluate the effects of placebo and two doses of bicarbonate on&#xD;
      urinary NTX and nitrogen excretion and on lower extremity performance over a three month&#xD;
      period. The lower dose is similar to the dose shown in our recent trial to be effective. This&#xD;
      study is a double blind, randomized, placebo-controlled, parallel-group trial in which 138&#xD;
      healthy men and 138 women, age 60 and older, will take potassium bicarbonate in doses of 1.0&#xD;
      or 1.5 mmol/kg of body weight or placebo daily for three months. Changes in urinary excretion&#xD;
      of NTX and nitrogen and in measures of lower extremity performance will be compared across&#xD;
      the three groups. The safety and tolerability of the interventions will also be evaluated.&#xD;
      This investigation should provide needed information on the appropriate dosing regimen and on&#xD;
      the study population that should be enrolled in a future bicarbonate intervention trial to&#xD;
      assess the long-term effects of this simple, low cost intervention on important clinical&#xD;
      outcomes including rates of loss in bone and muscle mass, falls, and fractures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide</measure>
    <time_frame>84 days</time_frame>
    <description>Describe and compare changes in urinary N-telopeptide (NTX) across the placebo and Potassium Bicarbonate (KHCO3) doses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary Aim - to Identify the Dose of KHCO3 Needed for Maximal Suppression of 24-hr Urinary Nitrogen</measure>
    <time_frame>84 days</time_frame>
    <description>Describe and compare changes in 24-hour urinary nitrogen in the low and high dose and KHCO3 group and in placebo.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Muscle Loss</condition>
  <condition>Fractures</condition>
  <condition>Osteoporosis, Age Related</condition>
  <condition>Fall Injury</condition>
  <arm_group>
    <arm_group_label>potassium bicarbonate low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>potassium bicarbonate higher dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>microcrystalline cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>potassium bicarbonate</intervention_name>
    <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
    <arm_group_label>potassium bicarbonate low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>potassium bicarbonate</intervention_name>
    <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
    <arm_group_label>potassium bicarbonate higher dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inactive placebo capsule</intervention_name>
    <description>microcrystalline cellulose</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  men and women&#xD;
&#xD;
          -  age 60 and older&#xD;
&#xD;
          -  community dwelling&#xD;
&#xD;
          -  women 1 yr since last menses&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medications:&#xD;
&#xD;
          1. Oral glucocorticoids for &gt; 10 days in the last 3 months&#xD;
&#xD;
               -  Cortef (hydrocortisone)&#xD;
&#xD;
               -  Prednisone&#xD;
&#xD;
          2. Parenteral glucocorticoids&#xD;
&#xD;
             • Decadron (dexamethasone)&#xD;
&#xD;
          3. Osteoporosis medications in the last 6 months&#xD;
&#xD;
               -  Forteo (teriparatide)&#xD;
&#xD;
               -  Calcimar, Miacalcin (calcitonin)&#xD;
&#xD;
               -  Evista (raloxifene)&#xD;
&#xD;
          4. Osteoporosis medications in the last 2 years&#xD;
&#xD;
               -  Fosamax (alendronate)&#xD;
&#xD;
               -  Didronel (etidronate)&#xD;
&#xD;
               -  Aredia (pamidronate)&#xD;
&#xD;
               -  Actonel (risedronate)&#xD;
&#xD;
               -  Reclast (zoledronate)&#xD;
&#xD;
          5. Tamoxifen in the last 6 months&#xD;
&#xD;
          6. Calcium/Parathyroid&#xD;
&#xD;
               -  Rocaltrol (calcitriol)&#xD;
&#xD;
               -  Zemplar (paricalcitol)&#xD;
&#xD;
               -  Drisdol, Ergocalciferol&#xD;
&#xD;
          7. Diuretics currently&#xD;
&#xD;
               -  hydrocholorothiazide (HCTZ)&#xD;
&#xD;
               -  Diuril (chlorothiazide)&#xD;
&#xD;
               -  Thalitone (chlorthalidone)&#xD;
&#xD;
               -  Zaroxolyn (metolazone)&#xD;
&#xD;
               -  Dyazide&#xD;
&#xD;
               -  Maxide&#xD;
&#xD;
               -  Moduretic&#xD;
&#xD;
               -  Lasix (forosamine)&#xD;
&#xD;
               -  Dyrenium (triamterene)&#xD;
&#xD;
               -  Midamor&#xD;
&#xD;
          8. Testosterone or estrogen in the last 6 months (vaginal estrogen okay)&#xD;
&#xD;
          9. Angiotensin converting enzyme (ACE) inhibitors currently&#xD;
&#xD;
               -  Benazepril (Lotensin)&#xD;
&#xD;
               -  Captopril (Capoten)&#xD;
&#xD;
               -  Enalapril (Vasotec)&#xD;
&#xD;
               -  Fosinopril (Monopril)&#xD;
&#xD;
               -  Lisinopril (Prinivil, Zestril)&#xD;
&#xD;
               -  Moexipril (Univasc)&#xD;
&#xD;
               -  Perindopril (Aceon)&#xD;
&#xD;
               -  Quinapril (Accupril)&#xD;
&#xD;
               -  Ramipril (Altace)&#xD;
&#xD;
               -  Trandolapril (Mavik)&#xD;
&#xD;
         10. Angiotensin II receptor blockers currently&#xD;
&#xD;
               -  Candesartan (Atacand)&#xD;
&#xD;
               -  Eprosartan (Teveten)&#xD;
&#xD;
               -  Irbesartan (Avapro)&#xD;
&#xD;
               -  Losartan (Cozaar)&#xD;
&#xD;
               -  Olmesartan (Benicar)&#xD;
&#xD;
               -  Telmisartan (Micardis)&#xD;
&#xD;
               -  Valsartan (Diovan)&#xD;
&#xD;
        Over-the-Counter Drugs currently&#xD;
&#xD;
          1. Antacids - any antacid that contains calcium carbonate, aluminum hydroxide, magnesium&#xD;
             hydroxide, or calcium acetate - selected examples include&#xD;
&#xD;
               -  TUMS&#xD;
&#xD;
               -  Mylanta&#xD;
&#xD;
               -  Maalox&#xD;
&#xD;
               -  Titralac&#xD;
&#xD;
               -  Rolaids&#xD;
&#xD;
               -  Sodium bicarbonate (baking soda)&#xD;
&#xD;
               -  Note: magaldrate or Riopan® is allowed&#xD;
&#xD;
          2. Potassium supplements&#xD;
&#xD;
          3. Salt substitutes&#xD;
&#xD;
        Conditions/Diseases&#xD;
&#xD;
          1. renal disease including kidney stones in the past 5 years or glomerular filtration&#xD;
             rate (GFR) &lt; 60 ml/min/1.73 m2&#xD;
&#xD;
          2. hyperkalemia (serum potassium &gt;5.3 meq/L; normal range 3.5-5.3 meq/L)&#xD;
&#xD;
          3. elevated serum bicarbonate (serum bicarbonate &gt; 29 mmol/L; normal range 22-29 mmol/L)&#xD;
&#xD;
          4. cirrhosis&#xD;
&#xD;
          5. gastroesophageal reflux disease (GERD) requiring treatment with alkali-containing&#xD;
             antacids (TUMS, Mylanta, Maalox, Titralac, Rolaids, or sodium bicarbonate)&#xD;
&#xD;
          6. hyperparathyroidism&#xD;
&#xD;
          7. untreated thyroid disease&#xD;
&#xD;
          8. significant immune disorder such as rheumatoid arthritis&#xD;
&#xD;
          9. current unstable heart disease&#xD;
&#xD;
         10. active malignancy or cancer therapy in the last year&#xD;
&#xD;
         11. fasting spot urine calcium/creatinine &gt; 0.38 mmol/mmol after 1 wk off of calcium&#xD;
             supplements&#xD;
&#xD;
         12. congestive heart failure, arrhythmias (surgically treated arrhythmias acceptable), or&#xD;
             myocardial infarction in last 12 months&#xD;
&#xD;
         13. serum calcium outside the normal range of 8.3-10.2 mg/dl&#xD;
&#xD;
         14. uncontrolled diabetes mellitus (fasting blood sugar &gt; 130)&#xD;
&#xD;
         15. alcohol use exceeding 2 drinks/day&#xD;
&#xD;
         16. peptic ulcers or esophageal stricture&#xD;
&#xD;
         17. weight &lt;45 or &gt;113.5 kg (&lt;99 or &gt;249.7 lbs)&#xD;
&#xD;
         18. other abnormalities in screening labs, at discretion of the study physician (the PI)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bess Dawson-Hughes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <results_first_submitted>June 10, 2015</results_first_submitted>
  <results_first_submitted_qc>September 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2015</results_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Bess Dawson-Hughes</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>potassium bicarbonate</keyword>
  <keyword>urinary N-telopeptide</keyword>
  <keyword>urinary nitrogen</keyword>
  <keyword>net acid excretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Potassium Bicarbonate Low Dose</title>
          <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="P2">
          <title>Potassium Bicarbonate Higher Dose</title>
          <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="P3">
          <title>Inactive Capsule</title>
          <description>microcrystalline cellulose&#xD;
placebo: microcrystalline cellulose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Potassium Bicarbonate Low Dose</title>
          <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="B2">
          <title>Potassium Bicarbonate Higher Dose</title>
          <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="B3">
          <title>Inactive Placebo Capsule</title>
          <description>microcrystalline cellulose&#xD;
placebo: microcrystalline cellulose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="244"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="5.5"/>
                    <measurement group_id="B2" value="66.4" spread="5.1"/>
                    <measurement group_id="B3" value="66.8" spread="6.1"/>
                    <measurement group_id="B4" value="66.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian, Non-hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian, Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.8" spread="13.7"/>
                    <measurement group_id="B2" value="74.2" spread="13.0"/>
                    <measurement group_id="B3" value="73.2" spread="14.0"/>
                    <measurement group_id="B4" value="74.1" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular Filtration Rate (GFR)</title>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" spread="13.2"/>
                    <measurement group_id="B2" value="77.5" spread="12.8"/>
                    <measurement group_id="B3" value="74.8" spread="12.9"/>
                    <measurement group_id="B4" value="76.3" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum potassium</title>
          <units>meq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.31" spread="0.29"/>
                    <measurement group_id="B2" value="4.39" spread="0.36"/>
                    <measurement group_id="B3" value="4.30" spread="0.31"/>
                    <measurement group_id="B4" value="4.33" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum bicarbonate</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="1.9"/>
                    <measurement group_id="B2" value="25.8" spread="2.4"/>
                    <measurement group_id="B3" value="26.1" spread="2.4"/>
                    <measurement group_id="B4" value="26.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine calcium/creatinine</title>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99" spread="43"/>
                    <measurement group_id="B2" value="99" spread="48"/>
                    <measurement group_id="B3" value="114" spread="69"/>
                    <measurement group_id="B4" value="104" spread="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide</title>
        <description>Describe and compare changes in urinary N-telopeptide (NTX) across the placebo and Potassium Bicarbonate (KHCO3) doses.</description>
        <time_frame>84 days</time_frame>
        <population>Healthy men and women age 60 years and older</population>
        <group_list>
          <group group_id="O1">
            <title>Potassium Bicarbonate Low Dose</title>
            <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
          </group>
          <group group_id="O2">
            <title>Potassium Bicarbonate Higher Dose</title>
            <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
          </group>
          <group group_id="O3">
            <title>Inactive Placebo Capsule</title>
            <description>microcrystalline cellulose&#xD;
placebo: microcrystalline cellulose</description>
          </group>
        </group_list>
        <measure>
          <title>The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide</title>
          <description>Describe and compare changes in urinary N-telopeptide (NTX) across the placebo and Potassium Bicarbonate (KHCO3) doses.</description>
          <population>Healthy men and women age 60 years and older</population>
          <units>nmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline 24-hr urinary NTX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240" spread="17"/>
                    <measurement group_id="O2" value="230" spread="20"/>
                    <measurement group_id="O3" value="241" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change in NTX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53" spread="11"/>
                    <measurement group_id="O2" value="-43" spread="11"/>
                    <measurement group_id="O3" value="-14" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Co-primary Aim - to Identify the Dose of KHCO3 Needed for Maximal Suppression of 24-hr Urinary Nitrogen</title>
        <description>Describe and compare changes in 24-hour urinary nitrogen in the low and high dose and KHCO3 group and in placebo.</description>
        <time_frame>84 days</time_frame>
        <population>healthy men and women age 60 years and older</population>
        <group_list>
          <group group_id="O1">
            <title>Potassium Bicarbonate Low Dose</title>
            <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
          </group>
          <group group_id="O2">
            <title>Potassium Bicarbonate Higher Dose</title>
            <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
          </group>
          <group group_id="O3">
            <title>Inactive Capsule</title>
            <description>microcrystalline cellulose&#xD;
placebo: microcrystalline cellulose</description>
          </group>
        </group_list>
        <measure>
          <title>Co-primary Aim - to Identify the Dose of KHCO3 Needed for Maximal Suppression of 24-hr Urinary Nitrogen</title>
          <description>Describe and compare changes in 24-hour urinary nitrogen in the low and high dose and KHCO3 group and in placebo.</description>
          <population>healthy men and women age 60 years and older</population>
          <units>mmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline 24-hr urine nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="769" spread="32"/>
                    <measurement group_id="O2" value="834" spread="39"/>
                    <measurement group_id="O3" value="864" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change in 24-hr urine nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.4" spread="18.6"/>
                    <measurement group_id="O2" value="-16.4" spread="19.1"/>
                    <measurement group_id="O3" value="-21.0" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>84 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Potassium Bicarbonate Low Dose</title>
          <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="E2">
          <title>Potassium Bicarbonate Higher Dose</title>
          <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water&#xD;
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="E3">
          <title>Inactive Capsule</title>
          <description>microcrystalline cellulose&#xD;
placebo: microcrystalline cellulose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal aortic repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <description>Bloating, dizziness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contusions/abrasions</sub_title>
                <description>Resulting from falls</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Fracture, right wrist, from fall</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>High serum potassium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <description>GI upset, heartburn, gas, bloating, nausea</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation/diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache, migraine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fever, fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mouth irritation</sub_title>
                <description>Roof of mouth irritation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee/hip injury</sub_title>
                <description>Sprain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <description>Reports numbness in thumb</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>High serum potassium</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Potassium level &gt; 5.3 meq/L</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>low GFR</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Reported if GFR &lt; 55; protocol change GFR &lt; 45</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bess Dawson-Hughes</name_or_title>
      <organization>Jean Mayer Human Nutrition Research Center on Aging at Tufts University</organization>
      <phone>617-556-3066</phone>
      <email>bess.dawson-hughes@tufts.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

